Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK, March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncol ...

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in Gastroenterology & Hepatology—the fifth peer-reviewed pu ...

Core Insights - Highmark Blue Cross Blue Shield has issued a positive coverage policy for Lucid Diagnostics' EsoGuard® Esophageal DNA Test, which will cover non-invasive screening for esophageal precancer and cancer in New York state [1][2] - This decision is seen as a landmark event for Lucid, potentially influencing other commercial insurers to adopt similar coverage policies and validating the strength of Lucid's clinical evidence [2] - Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, with its EsoGuard® test being the first commercially available tool aimed at early detection [3] Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [3] - The company aims to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk patients, utilizing its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device [3]

Core Viewpoint - Lucid Diagnostics Inc. is set to host a business update conference call on March 24, 2025, to discuss its operations and financial results, highlighting its growth strategy in cancer prevention diagnostics [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [4]. - The company offers the EsoGuard® Esophageal DNA Test, which is the first and only commercially available tool aimed at early detection of esophageal precancer in at-risk patients [4]. Financial Update - During the upcoming conference call, the Chief Financial Officer will present the financial results for the fourth quarter of 2024, providing insights into the company's financial performance [1].

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4] - Lucid's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection [4] Recent Financial Activity - The company announced the closing of a registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share [1] - Gross proceeds from this offering are approximately $15.3 million, with around $0.8 million in placement agent's fees and other expenses [2] - Canaccord Genuity acted as the sole placement agent for this offering [2] Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [2]

Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospit ...

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550( ...

Core Insights - Lucid Diagnostics has formed a strategic partnership with VITALExam to enhance access to its EsoGuard® Esophageal DNA Test for firefighters at risk of esophageal precancer [1][2] - The partnership aims to drive revenue through fully-contracted CheckYourFoodTube Precancer Testing Events, starting with an event at Tuscaloosa Fire Rescue [1][2] - Firefighters face a 62% increased risk of developing esophageal cancer and a 39% increased risk of dying from it, highlighting the need for early detection [3] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [4] - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [4] Partnership Details - The partnership with VITALExam is expected to enhance the health of first responders by integrating EsoGuard into their wellness programs [2] - VITALExam provides comprehensive medical care for first responders, including cancer screenings and physical assessments, utilizing advanced technology [2]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $1.2 million, representing a 20% increase quarter-on-quarter and a 50% increase year-on-year, marking a record quarterly revenue for the company [8][42] - Test volume for Q3 was 2,787, with a trailing three-month total of approximately 3,500 tests, the largest since the company's inception [42][43] - The quarterly burn rate was $10.4 million, consistent with the previous quarters, and included $7.3 million from ongoing operations [35] Business Line Data and Key Metrics Changes - The company has expanded its direct contracting initiatives, including the "Check Your Food Tube" events, which have tested over 7,000 firefighters with EsoGuard [9][10] - EsoGuard's gross margin per test remains over 90%, with a substantial commercial opportunity targeting approximately 30 million at-risk patients [15][16] Market Data and Key Metrics Changes - The total addressable market for EsoGuard is approximately $60 billion, with Medicare pricing established at $1,938 [15] - The company has seen a significant increase in claims submitted, with nearly 2,800 claims submitted in Q3, reflecting just under $7 million in pro forma revenue [49][50] Company Strategy and Development Direction - The company is focused on securing Medicare coverage for EsoGuard, having completed a comprehensive clinical evidence package and held productive meetings with the CMS [10][20] - Strategic initiatives include targeting concierge medicine and employer markets to drive contractually guaranteed revenue [22][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the upcoming submission for Medicare coverage, anticipating it to be a first-half event for next year [80] - The company is confident in its data package for both Medicare and commercial payers, which is expected to facilitate broader coverage discussions [88] Other Important Information - Cash at the end of Q3 was $14.5 million, with plans to increase cash runway by more than a quarter through new convertible note agreements [31][33] - The company has maintained a flat sales team headcount while focusing on revenue-driving programs [16][59] Q&A Session Summary Question: What caused the sequential decline in test volume in Q3? - Management noted that July had fewer large events due to summer, but volumes picked up in August and September, with October showing strong results [56][57] Question: Will Q4 be a record volume quarter? - Management indicated that while October was strong, holiday periods in December could affect volume predictability, but overall adoption is expanding [58][60] Question: What is the strategy for concierge medicine? - The company is entering the concierge medicine market, leveraging data and experience from previous employer market efforts to engage with practices [62][66] Question: What is the timeline for submitting the data package for Medicare coverage? - Management expects to submit the data package soon, with a high level of confidence in the outcome [79][80] Question: How will marketing strategy change with Medicare coverage? - The company plans to direct resources towards the Medicare population, which could increase revenue from that segment significantly [86][87] Question: How does pricing work in the concierge market? - Pricing will start at $2,500, with negotiations based on what practices believe their patients will pay, as this is a cash-pay model [84][85]

Nasdaq: LUCD Q3 2024 Business Update November 13, 2024 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the "Company") that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forwardlooking statements. ▪ Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Fa ...